Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Rapid-Release Griffithsin Fibers for the Dual Prevention of HSV-2 and HIV-1 Infections.

Tyo KM, Lasnik A, Zhang L, Jenson AB, Fuqua JL, Palmer KE, Steinbach-Rankins JM.

Antimicrob Agents Chemother. 2020 Mar 30. pii: AAC.02139-19. doi: 10.1128/AAC.02139-19. [Epub ahead of print]

PMID:
32229493
2.

Griffithsin Inhibits Nipah Virus Entry and Fusion and Can Protect Syrian Golden Hamsters From Lethal Nipah Virus Challenge.

Lo MK, Spengler JR, Krumpe LRH, Welch SR, Chattopadhyay A, Harmon JR, Coleman-McCray JD, Scholte FEM, Hotard AL, Fuqua JL, Rose JK, Nichol ST, Palmer KE, O'Keefe BR, Spiropoulou CF.

J Infect Dis. 2020 Feb 10. pii: jiz630. doi: 10.1093/infdis/jiz630. [Epub ahead of print]

PMID:
32037447
3.

Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections.

Tyo KM, Lasnik AB, Zhang L, Mahmoud M, Jenson AB, Fuqua JL, Palmer KE, Steinbach-Rankins JM.

J Control Release. 2020 Feb 5;321:84-99. doi: 10.1016/j.jconrel.2020.02.006. [Epub ahead of print]

PMID:
32035194
4.

Impact of Q-Griffithsin anti-HIV microbicide gel in non-human primates: In situ analyses of epithelial and immune cell markers in rectal mucosa.

Günaydın G, Edfeldt G, Garber DA, Asghar M, Noȅl-Romas L, Burgener A, Wählby C, Wang L, Rohan LC, Guenthner P, Mitchell J, Matoba N, McNicholl JM, Palmer KE, Tjernlund A, Broliden K.

Sci Rep. 2019 Dec 2;9(1):18120. doi: 10.1038/s41598-019-54493-4.

5.

Factors influencing rates of human papillomavirus vaccination.

Palmer KE, Moorman KL, Nickman NA, Owen DG.

Am J Health Syst Pharm. 2019 Dec 2;76(24):2053-2059. doi: 10.1093/ajhp/zxz246.

PMID:
31621875
6.

Design of Poly(lactic-co-glycolic Acid) (PLGA) Nanoparticles for Vaginal Co-Delivery of Griffithsin and Dapivirine and Their Synergistic Effect for HIV Prophylaxis.

Yang H, Li J, Patel SK, Palmer KE, Devlin B, Rohan LC.

Pharmaceutics. 2019 Apr 16;11(4). pii: E184. doi: 10.3390/pharmaceutics11040184.

7.

Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.

Diamos AG, Larios D, Brown L, Kilbourne J, Kim HS, Saxena D, Palmer KE, Mason HS.

Vaccine. 2019 Jan 3;37(1):137-144. doi: 10.1016/j.vaccine.2018.11.021. Epub 2018 Nov 17.

8.
9.

Technoeconomic Modeling of Plant-Based Griffithsin Manufacturing.

Alam A, Jiang L, Kittleson GA, Steadman KD, Nandi S, Fuqua JL, Palmer KE, Tusé D, McDonald KA.

Front Bioeng Biotechnol. 2018 Jul 24;6:102. doi: 10.3389/fbioe.2018.00102. eCollection 2018.

10.

Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates.

Girard L, Birse K, Holm JB, Gajer P, Humphrys MS, Garber D, Guenthner P, Noël-Romas L, Abou M, McCorrister S, Westmacott G, Wang L, Rohan LC, Matoba N, McNicholl J, Palmer KE, Ravel J, Burgener AD.

Sci Rep. 2018 May 23;8(1):8059. doi: 10.1038/s41598-018-26313-8.

11.

pH-responsive delivery of Griffithsin from electrospun fibers.

Tyo KM, Duan J, Kollipara P, Dela Cerna MVC, Lee D, Palmer KE, Steinbach-Rankins JM.

Eur J Pharm Biopharm. 2019 May;138:64-74. doi: 10.1016/j.ejpb.2018.04.013. Epub 2018 Apr 23.

PMID:
29698714
12.

Characterization of the hypersensitive response-like cell death phenomenon induced by targeting antiviral lectin griffithsin to the secretory pathway.

Kim BM, Lotter-Stark HCT, Rybicki EP, Chikwamba RK, Palmer KE.

Plant Biotechnol J. 2018 Oct;16(10):1811-1821. doi: 10.1111/pbi.12917. Epub 2018 May 2.

13.

Assessment of Pharmacy Department Patient Safety Culture with the Use of Validated Work Environment Survey Indices.

Rawlings JE, Herner SJ, Delate T, Palmer KE, Swartzendruber KA.

Perm J. 2018;22:17-070. doi: 10.7812/TPP/17-070.

14.

Pharmacokinetics of the Antiviral Lectin Griffithsin Administered by Different Routes Indicates Multiple Potential Uses.

Barton C, Kouokam JC, Hurst H, Palmer KE.

Viruses. 2016 Dec 17;8(12). pii: E331. doi: 10.3390/v8120331.

16.

Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV Infection.

Grooms TN, Vuong HR, Tyo KM, Malik DA, Sims LB, Whittington CP, Palmer KE, Matoba N, Steinbach-Rankins JM.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6518-6531. doi: 10.1128/AAC.00956-16. Print 2016 Nov.

17.

Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin.

Millet JK, Séron K, Labitt RN, Danneels A, Palmer KE, Whittaker GR, Dubuisson J, Belouzard S.

Antiviral Res. 2016 Sep;133:1-8. doi: 10.1016/j.antiviral.2016.07.011. Epub 2016 Jul 15.

18.

Bulk production of the antiviral lectin griffithsin.

Fuqua JL, Hamorsky K, Khalsa G, Matoba N, Palmer KE.

Plant Biotechnol J. 2015 Oct;13(8):1160-8. doi: 10.1111/pbi.12433. Epub 2015 Jul 14. Review.

19.

Improving the large scale purification of the HIV microbicide, griffithsin.

Fuqua JL, Wanga V, Palmer KE.

BMC Biotechnol. 2015 Feb 22;15:12. doi: 10.1186/s12896-015-0120-5.

20.

Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models.

Barton C, Kouokam JC, Lasnik AB, Foreman O, Cambon A, Brock G, Montefiori DC, Vojdani F, McCormick AA, O'Keefe BR, Palmer KE.

Antimicrob Agents Chemother. 2014;58(1):120-7. doi: 10.1128/AAC.01407-13. Epub 2013 Oct 21.

21.

Griffithsin protects mice from genital herpes by preventing cell-to-cell spread.

Nixon B, Stefanidou M, Mesquita PM, Fakioglu E, Segarra T, Rohan L, Halford W, Palmer KE, Herold BC.

J Virol. 2013 Jun;87(11):6257-69. doi: 10.1128/JVI.00012-13. Epub 2013 Mar 27.

22.

Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.

Hamorsky KT, Grooms-Williams TW, Husk AS, Bennett LJ, Palmer KE, Matoba N.

Antimicrob Agents Chemother. 2013 May;57(5):2076-86. doi: 10.1128/AAC.02588-12. Epub 2013 Feb 12.

23.

Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains.

Férir G, Huskens D, Palmer KE, Boudreaux DM, Swanson MD, Markovitz DM, Balzarini J, Schols D.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1513-23. doi: 10.1089/AID.2012.0026. Epub 2012 Jun 25.

24.

A multimeric L2 vaccine for prevention of animal papillomavirus infections.

Jagu S, Malandro N, Kwak K, Yuan H, Schlegel R, Palmer KE, Huh WK, Campo MS, Roden RB.

Virology. 2011 Nov 10;420(1):43-50. doi: 10.1016/j.virol.2011.07.020. Epub 2011 Sep 13.

25.

Griffithsin has antiviral activity against hepatitis C virus.

Meuleman P, Albecka A, Belouzard S, Vercauteren K, Verhoye L, Wychowski C, Leroux-Roels G, Palmer KE, Dubuisson J.

Antimicrob Agents Chemother. 2011 Nov;55(11):5159-67. doi: 10.1128/AAC.00633-11. Epub 2011 Sep 6.

26.

Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate.

Kouokam JC, Huskens D, Schols D, Johannemann A, Riedell SK, Walter W, Walker JM, Matoba N, O'Keefe BR, Palmer KE.

PLoS One. 2011;6(8):e22635. doi: 10.1371/journal.pone.0022635. Epub 2011 Aug 2.

27.

Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.

Férir G, Palmer KE, Schols D.

Virology. 2011 Sep 1;417(2):253-8. doi: 10.1016/j.virol.2011.07.004. Epub 2011 Jul 28.

28.

Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice.

Banerjee K, Michael E, Eggink D, van Montfort T, Lasnik AB, Palmer KE, Sanders RW, Moore JP, Klasse PJ.

AIDS Res Hum Retroviruses. 2012 Feb;28(2):206-14. doi: 10.1089/aid.2011.0101. Epub 2011 Jul 27.

29.

The porcine circovirus type 1 capsid gene promoter improves antigen expression and immunogenicity in a HIV-1 plasmid vaccine.

Tanzer FL, Shephard EG, Palmer KE, Burger M, Williamson AL, Rybicki EP.

Virol J. 2011 Feb 7;8:51. doi: 10.1186/1743-422X-8-51.

30.

Recombinant protein expression in Nicotiana.

Matoba N, Davis KR, Palmer KE.

Methods Mol Biol. 2011;701:199-219. doi: 10.1007/978-1-61737-957-4_11.

PMID:
21181532
31.

Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems.

Pogue GP, Vojdani F, Palmer KE, Hiatt E, Hume S, Phelps J, Long L, Bohorova N, Kim D, Pauly M, Velasco J, Whaley K, Zeitlin L, Garger SJ, White E, Bai Y, Haydon H, Bratcher B.

Plant Biotechnol J. 2010 Jun;8(5):638-54. Review.

32.

Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae.

O'Keefe BR, Giomarelli B, Barnard DL, Shenoy SR, Chan PK, McMahon JB, Palmer KE, Barnett BW, Meyerholz DK, Wohlford-Lenane CL, McCray PB Jr.

J Virol. 2010 Mar;84(5):2511-21. doi: 10.1128/JVI.02322-09. Epub 2009 Dec 23. Erratum in: J Virol. 2010 May;84(10):5456.

33.

Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer.

Palmer KE, Jenson AB, Kouokam JC, Lasnik AB, Ghim SJ.

Exp Mol Pathol. 2009 Jun;86(3):224-33. doi: 10.1016/j.yexmp.2009.01.009. Epub 2009 Feb 24. Review.

PMID:
19454268
34.

Display of peptides on the surface of tobacco mosaic virus particles.

Smith ML, Fitzmaurice WP, Turpen TH, Palmer KE.

Curr Top Microbiol Immunol. 2009;332:13-31. doi: 10.1007/978-3-540-70868-1_2. Review.

PMID:
19401819
35.

Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component.

O'Keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, Bakke J, Mirsalis J, d'Andrea AL, Hume SD, Bratcher B, Saucedo CJ, McMahon JB, Pogue GP, Palmer KE.

Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6099-104. doi: 10.1073/pnas.0901506106. Epub 2009 Mar 30.

36.

Viable chimaeric viruses confirm the biological importance of sequence specific maize streak virus movement protein and coat protein interactions.

van der Walt E, Palmer KE, Martin DP, Rybicki EP.

Virol J. 2008 May 20;5:61. doi: 10.1186/1743-422X-5-61.

37.

Genetically engineered Tobacco mosaic virus as nanoparticle vaccines.

McCormick AA, Palmer KE.

Expert Rev Vaccines. 2008 Feb;7(1):33-41. doi: 10.1586/14760584.7.1.33. Review.

PMID:
18251692
38.

Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide.

Emau P, Tian B, O'keefe BR, Mori T, McMahon JB, Palmer KE, Jiang Y, Bekele G, Tsai CC.

J Med Primatol. 2007 Aug;36(4-5):244-53.

PMID:
17669213
39.

Identification of long intergenic region sequences involved in maize streak virus replication.

Willment JA, Martin DP, Palmer KE, Schnippenkoetter WH, Shepherd DN, Rybicki EP.

J Gen Virol. 2007 Jun;88(Pt 6):1831-41.

PMID:
17485545
40.

Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsin.

Ziółkowska NE, Shenoy SR, O'Keefe BR, McMahon JB, Palmer KE, Dwek RA, Wormald MR, Wlodawer A.

Proteins. 2007 May 15;67(3):661-70.

PMID:
17340634
41.

Assembly of trans-encapsidated recombinant viral vectors engineered from Tobacco mosaic virus and Semliki Forest virus and their evaluation as immunogens.

Smith ML, Corbo T, Bernales J, Lindbo JA, Pogue GP, Palmer KE, McCormick AA.

Virology. 2007 Feb 20;358(2):321-33. Epub 2006 Oct 2.

42.

Chemical conjugate TMV-peptide bivalent fusion vaccines improve cellular immunity and tumor protection.

McCormick AA, Corbo TA, Wykoff-Clary S, Palmer KE, Pogue GP.

Bioconjug Chem. 2006 Sep-Oct;17(5):1330-8.

PMID:
16984144
43.

TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models.

McCormick AA, Corbo TA, Wykoff-Clary S, Nguyen LV, Smith ML, Palmer KE, Pogue GP.

Vaccine. 2006 Sep 29;24(40-41):6414-23. Epub 2006 Jul 5.

PMID:
16860441
44.

Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding.

Ziółkowska NE, O'Keefe BR, Mori T, Zhu C, Giomarelli B, Vojdani F, Palmer KE, McMahon JB, Wlodawer A.

Structure. 2006 Jul;14(7):1127-35.

45.

Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes.

Palmer KE, Benko A, Doucette SA, Cameron TI, Foster T, Hanley KM, McCormick AA, McCulloch M, Pogue GP, Smith ML, Christensen ND.

Vaccine. 2006 Jun 29;24(26):5516-25. Epub 2006 May 6.

PMID:
16725236
46.

Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications.

Smith ML, Lindbo JA, Dillard-Telm S, Brosio PM, Lasnik AB, McCormick AA, Nguyen LV, Palmer KE.

Virology. 2006 May 10;348(2):475-88. Epub 2006 Feb 8.

47.

2-Deoxy-D-glucose protects retinal ganglion cells against excitotoxicity.

Lan YW, Ishii Y, Palmer KE, Bristow KQ, Caprioli J, Kwong JM.

Neuroreport. 2003 Dec 19;14(18):2369-72.

PMID:
14663193
48.

Geminivirus vectors for high-level expression of foreign proteins in plant cells.

Mor TS, Moon YS, Palmer KE, Mason HS.

Biotechnol Bioeng. 2003 Feb 20;81(4):430-7. Erratum in: Biotechnol Bioeng. 2003 Mar 30;81(7):876.

PMID:
12491528
49.

Epigenetic modification of plants with systemic RNA viruses.

Fitzmaurice WP, Holzberg S, Lindbo JA, Padgett HS, Palmer KE, Wolfe GM, Pogue GP.

OMICS. 2002;6(2):137-51.

PMID:
12143960
50.

Supplemental Content

Loading ...
Support Center